FIGURE 1.
Time to next chemotherapy (A) and overall survival (B) of 112 patients with metastatic breast cancer treated with single‐agent pegylated liposomal doxorubicin (PLD) at the University Hospital Basel. Median time to next chemotherapy (A) was 4.6 months (95% confidence interval 3.6–5.6 months) and median overall survival (B) was 11.9 months (95% confidence interval 1.0–13.9 months).